Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

25.78USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$25.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,760,395
52-wk High
$29.93
52-wk Low
$21.03

Latest Key Developments (Source: Significant Developments)

Boston Scientific Receives FDA Approval For Vercise Deep Brain Stimulation System
Monday, 11 Dec 2017 05:04pm EST 

Dec 11 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE VERCISE™ DEEP BRAIN STIMULATION SYSTEM.BOSTON SCIENTIFIC CORP - DATA FROM INTREPID STUDY OF DBS SYSTEM IS EXPECTED TO BE RELEASED IN 2018.  Full Article

Appaloosa LP cuts share stake in BofA, dissolves share stake in Wells Fargo and Activision Blizzard
Tuesday, 14 Nov 2017 09:25am EST 

Nov 14 (Reuters) - APPALOOSA LP:Appaloosa LP dissolves share stake in Activision Blizzard Inc - SEC filing.Appaloosa LP cuts share stake in Bank Of America Corp by about 28 percent to 6.3 million shares.Appaloosa LP raises share stake in Boston Scientific Corp by about 66 percent to 3.8 million shares.Appaloosa LP dissolves share stake in L Brands Inc.Appaloosa LP dissolves share stake in Wells Fargo.Appaloosa LP cuts share stake in Dollar General Corp by 36 percent to 599,264 shares.Appaloosa LP raises share stake in NRG Energy Inc to 8.4 million shares from 1.3 million shares.Appaloosa LP - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.Source text for quarter ended Sept 30, 2017 (http://bit.ly/2zJRjl2).Source text for quarter ended June 30, 2017: (http://bit.ly/2uWm5mq).  Full Article

Boston Scientific announces results for third quarter 2017
Thursday, 26 Oct 2017 06:30am EDT 

Oct 26 (Reuters) - Boston Scientific Corp :Boston Scientific announces results for third quarter 2017.Q3 GAAP earnings per share $0.20.Sees FY 2017 revenue $8.985 billion to $9.015 billion.Q3 sales $2.222 billion versus I/B/E/S view $2.21 billion.Sees Q4 2017 GAAP earnings per share $0.19 to $0.23.Sees FY 2017 GAAP earnings per share $0.71 to $0.75.Q3 adjusted earnings per share $0.31.Sees Q4 2017 sales $2.345 billion to $2.375 billion.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Boston Scientific Corp qtrly Cardiac Rhythm Management sales of $‍​463 million versus $467 million.Boston Scientific Corp qtrly interventional cardiology sales of $589 million versus $568 million.Sees Q4 2017 adjusted earnings per share $0.32 to $0.35 excluding items.Q4 earnings per share view $0.34, revenue view $2.33 billion -- Thomson Reuters I/B/E/S.Boston Scientific Corp sees FY 2017 adjusted earnings per share ‍$1.24 to $1.27​ excluding items.Fy2017 earnings per share view $1.25, revenue view $8.95 billion -- Thomson Reuters I/B/E/S.  Full Article

Boston Scientific to buy Apama Medical
Monday, 2 Oct 2017 04:15pm EDT 

Oct 2 (Reuters) - Boston Scientific Corp :Boston Scientific announces agreement to acquire Apama Medical.Boston Scientific Corp - ‍transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over period of 2018-2020​.Boston Scientific Corp says ‍transaction is expected to be immaterial to boston scientific adjusted earnings per share for 2017 and 2018​.Boston Scientific - ‍on an adjusted basis, transaction is expected to be immaterial to boston scientific adjusted earnings per share for 2017 and 2018​.Boston Scientific - deal expected to be more dilutive on a gaap basis, due to amortization expense, transaction, integration related costs for 2017, 2018​.  Full Article

Boston Scientific announces positive late-breaking clinical trial data for Heartlogic Heart Failure Diagnostic
Tuesday, 19 Sep 2017 09:24am EDT 

Sept 19 (Reuters) - Boston Scientific Corp :Boston Scientific announces positive late-breaking clinical trial data for the Heartlogic Heart Failure Diagnostic.  Full Article

Veniti Inc announces Boston Scientific distribution agreement for VICI VENOUS STENT
Monday, 11 Sep 2017 08:00am EDT 

Sept 11 (Reuters) - Veniti Inc:‍Veniti Inc -Boston Scientific will distribute VICI VENOUS STENT under limited global distribution agreement; terms of agreement, specific regions, countries involved were not disclosed​.  Full Article

Boston Scientific Corp says entered into a $2.25 bln senior unsecured credit facility- SEC Filing
Monday, 7 Aug 2017 04:43pm EDT 

Aug 7 (Reuters) - Boston Scientific Corp :Boston Scientific Corp - on August 4, 2017, Boston Scientific Corporation entered into a $2.25 billion senior unsecured credit facility.Boston Scientific Corp - company may borrow from time to time up to $2.25 billion in revolving credit loans under 2017 credit agreement.Boston Scientific Corp - 2017 credit agreement matures on August 4, 2022.  Full Article

Boston Scientific outlines strategy for sustained growth at 2017 investor day
Tuesday, 27 Jun 2017 07:30am EDT 

June 27 (Reuters) - Boston Scientific Corp :Boston Scientific outlines strategy for sustained growth at 2017 investor day.Continues to expect to launch Lotus Edge valve system in Europe and submit U.S. pre-market approval submission in Q4 of 2017.Company expects to introduce vercise dbs system in U.S. by early 2018, pending regulatory approval.Goal is to achieve an organic revenue compound annual growth rate for 2018-2020 of six to eight percent.Goal is to achieve consistent double-digit adjusted EPS growth for 2018-2020.Five-year growth strategy intended to help reach a 25 percent adjusted operating margin in 2017 and 28 percent in 2020.  Full Article

Boston Scientific receives CE mark for Vercise Gevia deep brain stimulation system
Tuesday, 6 Jun 2017 06:30am EDT 

June 6 (Reuters) - Boston Scientific Corp ::Boston Scientific receives CE mark for Vercise™ Gevia™ deep brain stimulation system.Boston Scientific - ‍approval expands Vercise directional portfolio which is composed of Vercise primary cell, Vercise Gevia platforms.  Full Article

Boston Scientific announces positive results from the Reprise III clinical trial
Tuesday, 16 May 2017 06:47am EDT 

May 16 (Reuters) - Boston Scientific Corp :The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year.Boston Scientific Corp says LOTUS valve system also demonstrated non-inferiority to corevalve platform for primary safety endpoint.Boston Scientific - secondary endpoint demonstrated LOTUS valve system had lower rates of moderate to severe pvl occurrences compared to corevalve platform.Boston Scientific Corp - LOTUS valve system showed superiority over corevalve tavi system platform for primary effectiveness endpoint.  Full Article

Boston Scientific loses bid to dismiss defibrillator whistleblower case

A federal judge has allowed to proceed a whistleblower lawsuit claiming Boston Scientific Corp caused doctors to make false claims for reimbursement from federal healthcare programs for two defective defibrillator products.